Evolving paradigms: IL-5's role in eosinophilic pathologies and targeted treatments

1,378
Total views and downloads

Participate in this topic

Articles

ORIGINAL RESEARCH

Accepted on 06 Oct 2025

Benralizumab for Adults with Rare and Off-Label Eosinophilic disorders: a 52-week Prospective, Single-Center Study

Aviv Talmon
Oded Shamriz
Limor Rubin
Yaarit Ribak
Iris Aynor
Adam Nevo
Anna Elia
Meitav Ben Sion
Esther Forkosh
1 more
Yuval Tal

doi 10.3389/fimmu.2025.1702989

Share on

Frontiers in Immunology

Frontiers in Immunology

Inflammation

Manuscripts can be submitted to this Research Topic via the main journal or any other participating journal.

Impact

1,378Topic views